|
May 9
|
Psychedelic: Compass, GH Research, MindMed report quarterly earnings
|
|
May 8
|
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates
|
|
Mar 22
|
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
|
|
Mar 21
|
Psychedelic: atai Life Sciences, NRx report quarterly results
|
|
Mar 17
|
MindMed Appoints Matt Wiley as Chief Commercial Officer
|
|
Jul 29
|
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
|
|
Jun 21
|
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
Jun 20
|
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
|
|
May 9
|
MindMed to Participate at May Investor Conferences
|
|
May 9
|
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
|
|
May 8
|
MindMed Reports First Quarter 2024 Financial Results and Business Updates
|
|
May 4
|
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
|
|
May 2
|
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
|
|
Apr 25
|
MindMed to Present at Upcoming May Medical Conferences
|
|
Apr 2
|
MindMed to Present at Upcoming April Medical Conferences
|
|
Apr 1
|
MindMed Announces Voluntary Delisting from Cboe Canada
|
|
Mar 11
|
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
|
|
Mar 10
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Mar 7
|
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
|
|
Mar 7
|
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
|